-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GRdXBWrHmgLxZwn27nDsEjcZIXg/QNzB1ibWGhQATjF42Oe3VhETrSeuhTIbrw5v iS51ZB2JxfteSaPVX4ZvuQ== 0001299933-06-005335.txt : 20060809 0001299933-06-005335.hdr.sgml : 20060809 20060809161455 ACCESSION NUMBER: 0001299933-06-005335 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20060809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060809 DATE AS OF CHANGE: 20060809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TLC VISION CORP CENTRAL INDEX KEY: 0001010610 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 980151150 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29302 FILM NUMBER: 061017786 BUSINESS ADDRESS: STREET 1: 5280 SOLAR DRIVE STREET 2: SUITE 100 CITY: MISSISSAUGA ONTARIO STATE: A6 ZIP: 00000 BUSINESS PHONE: 636-534-2300 MAIL ADDRESS: STREET 1: 16305 SWINGLEY RIDGE ROAD STREET 2: SUITE 300 CITY: CHESTERFIELD STATE: MO ZIP: 63017 FORMER COMPANY: FORMER CONFORMED NAME: TLC LASER CENTER INC DATE OF NAME CHANGE: 19960314 8-K 1 htm_14315.htm LIVE FILING TLC Vision Corporation (Form: 8-K)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   August 9, 2006

TLC Vision Corporation
__________________________________________
(Exact name of registrant as specified in its charter)

     
New Brunswick 0-29302 980151150
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
5280 Solar Drive, Suite 100, Mississauga, Ontario   L4W 5M8
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   (905) 602-2020

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02 Results of Operations and Financial Condition.

On August 9, 2006 TLC Vision Corporation issued a press release announcing its financial results for the second quarter and six months ended June 30, 2006. A copy of the press release is attached hereto and incorporated herein as Exhibit 99.1.
This form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.





Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1 - August 9, 2006 Press Release regarding financial results






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    TLC Vision Corporation
          
August 9, 2006   By:   /s/ Brian L. Andrew
       
        Name: Brian L. Andrew
        Title: General Counsel


Exhibit Index


     
Exhibit No.   Description

 
99.1
  August 9, 2006 Press Release, Financials
EX-99.1 2 exhibit1.htm EX-99.1 EX-99.1
     
News Release
  Contact:
For Immediate Release
  Anna Austin, EVP, Corporate Communications
(636) 534-2271
Email: investor.relations@tlcvision.com

TLCVision Reports Second Quarter Earnings of $0.16 Per Share;

Strategic Initiatives Drive 14% Revenue Increase

ST. LOUIS, MO, August 9, 2006: TLC Vision Corporation (NASDAQ:TLCV; TSX:TLC), North America’s premier eye care services company, today announced its financial results for the second quarter and six months ended June 30, 2006. All dollar amounts are expressed in U.S. currency and results are reported in accordance with U.S. generally accepted accounting principles (U.S. GAAP) unless otherwise noted.

Editor’s Note: “Operating Business” (or “Operating”) is defined as TLCVision’s activities excluding the impact of the AMD segment, representing our investment in OccuLogix, Inc. To provide maximum transparency for investors, Operating Business financial results are listed separately from consolidated results in this press release.

“TLCVision demonstrated this quarter that our strategic initiatives are delivering results,” said Jim Wachtman, President and Chief Executive Officer. “These results were achieved with contribution from all of our business segments. The Company delivered overall revenue growth and refractive procedure volume growth in our core centers, despite a slowdown in the industry. With 84 refractive centers and double digit growth in our Other Healthcare Services segment, we are positioned well for the future.”

SECOND QUARTER HIGHLIGHTS:

    14% revenue growth.

    4% increase in refractive centers procedure volume (including LECC).

    Over 20% revenue growth in Other Healthcare Services.

    Earnings per share of $0.16 (including a cumulative income tax benefit).

    Continued strong operating cash flow of $0.20 per share.

REVENUES

TLCVision’s second quarter revenues were $76.2 million, an increase of over 14% from 2005.

    Total refractive revenues were up 12% to $53.4 million, reflecting higher average selling prices in the centers business, the benefit of 2005 acquisitions and the early contribution from our value-priced strategy. Center revenues were 15% higher during the quarter, and total refractive center procedure volumes (including LECC) were 31,900, up over 4% from prior year, despite softness in the overall industry. Access revenues were down only 1%, the smallest decline in six quarters.

    Other Healthcare Services revenues (excluding AMD) increased 24% to $22.8 million, with strong growth in our cataract business of 23%. Total surgical procedures of 19,300 were 8% above prior year. Vision Source grew by 19% over the same period in 2005.

EARNINGS

Consolidated: Net income for the second quarter was $10.9 million, including the AMD net loss of $0.4 million.

Operating Business: Net income for the quarter of $11.3 million (or $0.16 per fully diluted share) was more than double prior year reported results of $5.2 million (or $0.07 per share). Excluding both the cumulative income tax benefit noted below and the benefit of reducing the Company’s effective tax rate from the 38% rate applied last quarter, the resulting pro forma net income would have been $5.4 million (or $0.08 per fully diluted share), 25% higher than the comparable pro forma results in 2005 on a per share basis.

During the quarter, TLCVision completed its analysis of available net operating losses and evaluation of its income tax accounting. The findings and conclusions reached include the following:

    We have decided to restate our 2005 Form 10-K to record $1.2 million of income tax expense from 2005 (where it was originally recorded and disclosed) to 2004. This adjustment will have no impact on 2006 results.

    The Company confirmed that it has net operating loss carryforwards of approximately $187 million available to offset future taxable income. This amount was significantly higher than estimated at the end of 2005.

    Reflecting the new level of net operating loss carryforwards, the Company recorded a cumulative adjustment to our income tax accounts, resulting in a one-time benefit of $3.4 million.

    The Company reduced its effective tax rate from a 38% historic rate to approximately 12% for the full year 2006.

STRONG CASH GENERATION

Operating cash flow for the second quarter was $13.8 million, or $0.20 per fully diluted share. The Company continues to maintain a strong financial position, with cash and short-term investments totaling $45.7 million.

YEAR-TO-DATE RESULTS

For the six months ended June 30, 2006, revenues grew 12% to $153.8 million from $137.9 million for the six months ended June 30, 2005. Total centers procedure volume (including LECC) was 67,000, a 2% increase from prior year. Other Healthcare Services revenues increased 19% to $41.5 million.

For the six months ended June 30, 2006, consolidated net income was $13.6 million including a net $3.2 million loss from the AMD segment. Net income for the Operating Business was $16.8 million or $0.24 per share, a 28% increase over prior year on a per-share basis.

Consolidated operating cash flow for the six month period was $22.8 million. Operating cash flow for the Operating Business was $27.7 million or $0.40 per share.

2006 OPERATING BUSINESS FINANCIAL GUIDANCE

Reflecting the financial results for the first six months of the year, as well as factoring in the revised refractive industry growth rates for 2006 and the retiming of planned ambulatory surgery center acquisitions, we are updating our 2006 guidance for the Operating Business as follows:

    Net revenues are now anticipated to be between $290 million and $300 million, or a growth of between 12% and 16% from full year 2005 results, reflecting the lower overall growth prospects for the refractive industry and the delay in closing of planned ASC acquisitions.

    While the level of pre-tax earnings is not anticipated to change, as a result of the favorable income tax adjustments noted earlier and the lower overall effective tax rate, fully taxed earnings per share are now anticipated to be between $0.30 to $0.33.

    Operating cash flow per share guidance has been maintained at between $0.58 and $0.62.

“While we are decreasing our revenue guidance to better reflect current market conditions, we are holding to our expectations for earnings and cash flow,” said Jim Wachtman. “We continue to have confidence in the strategy that we are executing to grow the Company.”

CONFERENCE CALL

TLCVision is pleased to invite all interested parties to participate in a conference call during which these results will be discussed. The call will be held today, August 9, at 4:30 pm Eastern Time at 1-877-888-3490. The call will also be broadcast live and archived on the Company’s web site at www.tlcv.com under the “Webcasts” link in the Investor Relations section. In addition, the live web cast will be available at various other popular portals and financial web sites. A replay will be available until August 23 by dialing 1-888-509-0081 and entering pass code 628166.

About TLCVision

TLCVision is North America’s premier eye care services company, providing eye doctors with the tools and technologies needed to deliver high-quality patient care. Through its centers management and technology access service models, and its managed care contracting strength, TLCVision maintains leading positions in Refractive and Cataract markets. More information about TLCVision can be found on the corporate website www.tlcv.com. Go to www.tlcvision.com or www.lasikselectvision.com for information on refractive surgery.

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934, which statements can be identified by the use of forward looking terminology, such as “may”, “will”, “expect”, ”intend”, “anticipate”, “estimate”, “predict”, “plans” or “continue” or the negative thereof or other variations thereon or comparable terminology referring to future events or results. The Company’s actual results could differ materially from those anticipated in these forward looking statements as a result of numerous factors, including the timing of expenditures, effects of competition, changes to pricing, acquisitions and expansion opportunities, any of which could cause actual results to vary materially from current results or TLCVision’s anticipated future results. See the Company’s reports filed with the Canadian Securities Regulators and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward looking statements. TLCVision assumes no obligation to update the information contained in this press release.

                                                 
            Three Months Ended                    
        June 30, 2006           Three Months Ended June 30, 2005 (As Restated)
                            Results Before AMD        
    Results Before AMD Segment   AMD Segment   Total TLCVision   Segment   AMD Segment   Total TLCVision
Revenues:
                                               
Refractive:
                                               
Centers
  $ 43,598     $     $ 43,598     $ 38,010     $     $ 38,010  
Access
    9,771             9,771       9,828             9,828  
Other healthcare services
    22,846             22,846       18,414       568       18,982  
 
                                               
Total revenues
    76,215             76,215       66,252       568       66,820  
Cost of revenues:
                                               
Refractive:
                                               
Centers
    29,908             29,908       25,921             25,921  
Access
    7,160             7,160       7,200             7,200  
Other healthcare services
    13,946             13,946       10,697       510       11,207  
 
                                               
Total cost of revenues
    51,014             51,014       43,818       510       44,328  
 
                                               
Gross profit
    25,201             25,201       22,434       58       22,492  
 
                                               
General and administrative
    7,085             7,085       7,232       1,995       9,227  
Marketing and sales
    6,704             6,704       5,656       187       5,843  
Research and development, clinical and regulatory
                            1,310       1,310  
Amortization of intangibles
    874             874       1,032             1,032  
Other expenses (income), net
    (169 )           (169 )     (363 )           (363 )
Total operating costs
    14,494             14,494       13,557       3,492       17,049  
 
                                               
Operating income (loss)
    10,707             10,707       8,877       (3,434 )     5,443  
Gain on sale of OccuLogix, Inc. stock
          1,450       1,450                    
Interest income
    222             222       558       421       979  
Interest expense
    (141 )           (141 )     (184 )           (184 )
Minority interests
    (2,938 )           (2,938 )     (2,516 )     1,411       (1,105 )
Earnings (losses) from equity investments
    951       (1,850 )     (899 )     680             680  
 
                                               
Income (loss) before income taxes
    8,801       (400 )     8,401       7,415       (1,602 )     5,813  
Income tax benefit (expense)
    2,466             2,466       (2,178 )           (2,178 )
 
                                               
Net income (loss)
  $ 11,267     $ (400 )   $ 10,867     $ 5,237     $ (1,602 )   $ 3,635  
 
                                               
Earnings (loss) per share — diluted
  $ 0.16     $ 0.00     $ 0.16     $ 0.07     $ (0.02 )   $ 0.05  
 
                                               
Weighted average number of common shares outstanding — diluted
    69,830       69,830       69,830       72,071       72,071       72,071  
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
                                               
TLC VISION CORPORATION
                                               
CONSOLIDATING STATEMENTS OF OPERATIONS (UNAUDITED)
                                               
(In thousands except per share amounts)
                                               
 
          Six Months Ended
                               
 
          June 30, 2006           Six Months Ended June 30, 2005 (As Restated)
                             
 
                          Results Before AMD
               
 
  Results Before AMD Segment
  AMD Segment
  Total TLCVision
  Segment
  AMD Segment
  Total TLCVision
 
                                               
Revenues:
                                               
Refractive:
                                               
Centers
  $ 91,537     $     $ 91,537     $ 81,775     $     $ 81,775  
Access
    20,759             20,759       21,239             21,239  
Other healthcare services
    41,500             41,500       33,855       1,000       34,855  
 
                                               
Total revenues
    153,796             153,796       136,869       1,000       137,869  
Cost of revenues:
                                               
Refractive:
                                               
Centers
    61,796             61,796       54,450             54,450  
Access
    14,675             14,675       14,610             14,610  
Other healthcare services
    25,273       1,659       26,932       20,328       1,030       21,358  
 
                                               
Total cost of revenues
    101,744       1,659       103,403       89,388       1,030       90,418  
 
                                               
Gross profit (loss)
    52,052       (1,659 )     50,393       47,481       (30 )     47,451  
 
                                               
General and administrative
    16,153       1,759       17,912       14,411       3,876       18,287  
Marketing and sales
    13,506       169       13,675       10,468       372       10,840  
Research and development, clinical and regulatory
          1,475       1,475             2,654       2,654  
Amortization of intangibles
    1,738             1,738       2,043             2,043  
Other expenses (income), net
    (526 )     849       323       (1,033 )           (1,033 )
Total operating costs
    30,871       4,252       35,123       25,889       6,902       32,791  
 
                                               
Operating income (loss)
    21,181       (5,911 )     15,270       21,592       (6,932 )     14,660  
Gain on sale of OccuLogix, Inc. stock
          1,450       1,450                    
Interest income
    869       366       1,235       1,275       776       2,051  
Interest expense
    (679 )           (679 )     (642 )           (642 )
Minority interests
    (5,467 )     2,715       (2,752 )     (4,701 )     2,910       (1,791 )
Earnings (losses) from equity investments
    1,874       (1,850 )     24       1,339             1,339  
 
                                               
Income (loss) before income taxes
    17,778       (3,230 )     14,548       18,863       (3,246 )     15,617  
Income tax expense
    (969 )           (969 )     (5,255 )           (5,255 )
 
                                               
Net income (loss)
  $ 16,809     $ (3,230 )   $ 13,579     $ 13,608     $ (3,246 )   $ 10,362  
 
                                               
Earnings (loss) per share — diluted
  $ 0.24     $ (0.05 )   $ 0.19     $ 0.19     $ (0.05 )   $ 0.14  
 
                                               
Weighted average number of common shares outstanding — diluted
    69,832       69,832       69,832       72,057       72,057       72,057  
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
                                               
TLC VISION CORPORATION
                                               
CONSOLIDATING BALANCE SHEETS
                                               
(In thousands)
                                               
 
          June 30, 2006
                               
 
          (Unaudited)
                  December 31, 2005
       
 
                                               
 
                          Results Before AMD
  AMD Segment
       
 
  Results Before AMD Segment
  AMD Segment
  Total TLCVision
  Segment (Unaudited)
  (Unaudited)
  Total TLCVision
 
                                               
ASSETS
                                               
Current assets
                                               
Cash and cash equivalents
  $ 35,869     $ 10     $ 35,879     $ 22,122     $ 9,607     $ 31,729  
Short-term investments
    9,825             9,825       6,550       31,663       38,213  
Accounts receivable, net
    19,811             19,811       20,056       527       20,583  
Prepaid expenses, inventory and other
    12,053             12,053       11,604       5,519       17,123  
 
                                               
Total current assets
    77,558       10       77,568       60,332       47,316       107,648  
Intercompany
    (565 )     565             1,693       (1,693 )      
Restricted cash
    1,010             1,010       975             975  
Investments and other assets
    21,712       18,278       39,990       19,838             19,838  
Goodwill
    96,440             96,440       99,402             99,402  
Other intangible assets, net
    22,249             22,249       23,886       135       24,021  
Fixed assets, net
    53,117             53,117       48,646       513       49,159  
 
                                               
Total assets
  $ 271,521     $ 18,853     $ 290,374     $ 254,772     $ 46,271     $ 301,043  
 
                                               
LIABILITIES
                                               
Current liabilities
                                               
Accounts payable
  $ 9,675     $     $ 9,675     $ 10,517     $ 514     $ 11,031  
Accrued liabilities
    21,715             21,715       22,158       2,295       24,453  
Current maturities of long-term debt
    6,595             6,595       5,268             5,268  
 
                                               
Total current liabilities
    37,985             37,985       37,943       2,809       40,752  
Long-term debt, less current maturities
    14,236             14,236       12,665             12,665  
Other long-term liabilities
    3,132             3,132       3,427             3,427  
Minority interests
    14,696             14,696       14,284       21,510       35,794  
 
                                               
Total liabilities
    70,049             70,049       68,319       24,319       92,638  
STOCKHOLDERS’ EQUITY
                                               
Common stock
    418,193       30,898       449,091       419,936       30,767       450,703  
Option and warrant equity
    1,814             1,814       1,861             1,861  
Accumulated deficit
    (218,535 )     (12,045 )     (230,580 )     (235,344 )     (8,815 )     (244,159 )
 
                                               
Total stockholders’ equity
    201,472       18,853       220,325       186,453       21,952       208,405  
 
                                               
 
                                               
Total liabilities and stockholders’ equity
  $ 271,521     $ 18,853     $ 290,374     $ 254,772     $ 46,271     $ 301,043  
 
                                               
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
                                               
TLC VISION CORPORATION
                                               
CONSOLIDATING STATEMENTS OF CASH FLOWS (UNAUDITED)
                                               
(In thousands except per share amounts)
                                               
 
          Six Months Ended
                               
 
          June 30, 2006           Six Months Ended June 30, 2005 (As Restated)
      -               -      
 
                          Results Before AMD
               
 
  Results Before AMD Segment
  AMD Segment
  Total TLCVision
  Segment
  AMD Segment
  Total TLCVision
 
                                               
OPERATING ACTIVITIES
                                               
Net income (loss)
  $ 16,809     $ (3,230 )   $ 13,579     $ 13,608     $ (3,246 )   $ 10,362  
Adjustments to reconcile net income (loss) to net cash from operating activities:
                                               
Depreciation and amortization
    7,642       34       7,676       7,929       59       7,988  
Reimbursements from investments in research and development
                                               
arrangements
    (300 )           (300 )     (300 )           (300 )
Minority interests
    5,467       (2,715 )     2,752       4,701       (2,910 )     1,791  
(Earnings) losses from equity investments
    (1,874 )     1,850       (24 )     (1,339 )           (1,339 )
Deferred taxes
    2,019             2,019       4,126             4,126  
Loss (gain) on sales and disposals of fixed assets
    (28 )     29       1       (96 )           (96 )
Gain on sale of OccuLogix, Inc. stock
          (1,450 )     (1,450 )                  
Write-down of OccuLogix, Inc. inventory
          1,625       1,625                    
Gain on sale of subsidiary
                      (319 )           (319 )
Non-cash compensation expense
    739       186       925       69       137       206  
Other
          26       26             88       88  
Changes in operating assets and liabilities, net of acquisitions and dispositions:
    (2,823 )     (1,225 )     (4,048 )     (5,039 )     (4,711 )     (9,750 )
 
                                               
Cash from operating activities
    27,651       (4,870 )     22,781       23,340       (10,583 )     12,757  
 
                                               
INVESTING ACTIVITIES
                                               
Purchases of fixed assets
    (6,349 )           (6,349 )     (5,113 )     (64 )     (5,177 )
Proceeds from sales of fixed assets
    516             516       724             724  
Proceeds from divestitures of investments and subsidiaries, net
                      3,430             3,430  
Proceeds from sale of OccuLogix, Inc. stock, net
          2,226       2,226                    
OccuLogix, Inc. cash balance at time of deconsolidation
          (14,814 )     (14,814 )                  
Distributions and loan payments received from equity investments
    1,854             1,854       1,387             1,387  
Reimbursements from investments in research and development
                                               
arrangements
    300             300       300             300  
Acquisitions and equity investments
    (3,171 )           (3,171 )     (8,881 )           (8,881 )
Proceeds from sales of short-term investments
          9,925       9,925       56,350       10,047       66,397  
Purchases of short-term investments
    (3,275 )           (3,275 )     (27,710 )     (5,383 )     (33,093 )
Other
    24       (71 )     (47 )     35       (42 )     (7 )
 
                                               
Cash from investing activities
    (10,101 )     (2,734 )     (12,835 )     20,522       4,558       25,080  
 
                                               
FINANCING ACTIVITIES
                                               
Restricted cash movement
    (35 )           (35 )     25             25  
Transfer proceeds from sale of OccuLogix, Inc. stock, net
    2,226       (2,226 )                        
Principal payments of debt financing and capital leases
    (1,968 )           (1,968 )     (6,131 )           (6,131 )
Proceeds from debt financing
    283             283       1,321             1,321  
Distributions to minority interests
    (4,754 )           (4,754 )     (3,744 )           (3,744 )
Proceeds from issuances of common stock
    445             445       1,089             1,089  
Proceeds from issuances of OccuLogix, Inc. stock
          233       233             107       107  
 
                                               
Cash from financing activities
    (3,803 )     (1,993 )     (5,796 )     (7,440 )     107       (7,333 )
 
                                               
Net increase (decrease) in cash and cash equivalents during the period
    13,747       (9,597 )     4,150       36,422       (5,918 )     30,504  
Cash and cash equivalents, beginning of period
    22,122       9,607       31,729       15,847       17,588       33,435  
 
                                               
Cash and cash equivalents, end of period
  $ 35,869     $ 10     $ 35,879     $ 52,269     $ 11,670     $ 63,939  
 
                                               
Operating cash flow per diluted share
  $ 0.40     $ (0.07 )   $ 0.33     $ 0.32     $ (0.14 )   $ 0.18  
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
                                               

-----END PRIVACY-ENHANCED MESSAGE-----